PepGen Inc. (PEPG) stock analysis
In our weekly check, PepGen Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 4 pass, warnings: 2, red flags: 12.
About PepGen Inc.
PepGen Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PEPG.
What our checks show for PEPG
Red flags
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- Weak EPS forecast
- Analysts expect the net margin to shrink by 170 points from today's 0%.
- Earnings per share fell 34.7% a year over the last 3 years.
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 172% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 95% from a peak. Would you have held through that?
- Beta 2.01: the stock usually moves more than the market, both up and down.
- The share count grew by 77.4% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- A small company (market value $302 million): usually riskier and followed by fewer analysts.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0.15x equity.
- Actively traded: about 2.9 million shares a day.
Similar companies
MPLT · KYTX · LRMR · BNTC · XFOR · ALT
Questions
What grade does PepGen Inc. (PEPG) have?
In our weekly check, PepGen Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 4 pass, warnings: 2, red flags: 12. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of PEPG stock?
This week's biggest flags for PepGen Inc.: Profits not backed by cash, Weak EPS forecast, Margins expected to shrink. In total 14 of 18 checks show a warning or a red flag.
What does PepGen Inc. do?
PepGen Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PEPG.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis